This trial is active, not recruiting.

Condition gram-negative bacterial infections
Sponsor University of Pittsburgh
Collaborator Celgene Corporation
Start date September 2005
End date December 2016
Trial size 1000 participants
Trial identifier NCT00177814, IRB # 0508074


The proposed endpoints of the study would be: comparative use of piperacillin versus broader spectrum agents (e.g., piperacillin/tazobactam, etc.) [measured as defined daily doses per 1000 patient days]; physician acceptance of piperacillin as part of a streamlining program [measured as successful occurrences of the use of piperacillin as streamlining therapy]; changes in susceptibility patterns of broad spectrum antibiotics [measured as % Gram negative bacilli susceptible to each of the commonly used broad spectrum antibiotics]; and outcome of patients treated with streamlined therapy.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective retrospective

Primary Outcomes

dead or alive
time frame: end of study

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients with Gram negative infections treated with piperacillin/tazobactam and/or piperacillin

Additional Information

Official title Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
Principal investigator David Paterson, MD
Description The following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, recent immunomodulative therapies, physical exam findings, laboratory and radiographical data, antimicrobial usage, microbiological data and resistance patterns, choice of antibiotics once organism is identified, suspected source of infection, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome, gender, height, weight, ethnicity, and past medical history.
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by University of Pittsburgh.